NeuroTrauma Sciences (NTS), founded in 2016, is a biopharmaceutical company developing novel therapeutics for the treatment of CNS injury, with a focus on stroke and traumatic brain injury (TBI). Millions of patients worldwide suffering from lifelong stroke or TBI injuries have limited therapeutic options to alleviate their cognitive, neuromotor, and neurobehavioral deficits. This massively underserved population drives our focused efforts to revolutionize treatments.

NTS is developing neuroprotective, anti-inflammatory small molecules that modify injury-induced cell death and dysfunction. We collaborate with with leading investigators to ensure the highest quality translational and clinical data.

By capitalizing on lessons learned from previous stroke and TBI clinical trials, NTS is developing a platform of acute and chronic therapies. NTS is utilizing technological advances of the past decade including state-of-the-art imaging and biomarker diagnostics to optimize clinical trial design and maximize patient outcomes.